A new nationwide study out of Taiwan adds fresh weight to the growing list of potential benefits offered by GLP-1 receptor agonists (GLP-1RAs)—a class of medications already known for their glycemic control, cardiovascular protection, and weight loss benefits. This time, the focus is on something more insidious: infections that land people in the hospital.
In a retrospective cohort study published in Diabetes Research and Clinical Practice, Wang and colleagues examined over 455,000 individuals with type 2 diabetes and found that those who initiated therapy with a GLP-1RA had significantly fewer hospitalizations due to lower respiratory tract infections and diabetic foot infections compared to those taking DPP-4 inhibitors (another class of glucose-lowering agents).
🔍 What Did the Study Find?
After performing a robust 1:1 propensity score match—yielding over 17,000 well-matched patients in each group—the researchers found:
- 44% lower risk of hospitalization for lower respiratory tract infections among GLP-1RA users (adjusted HR 0.56, 95% CI 0.49–0.65).
- 23% lower risk of hospitalization for diabetic foot infections (adjusted HR 0.77, 95% CI 0.65–0.91).
- No significant difference for intraabdominal or genitourinary infections.
These findings remained consistent across subgroups, including patients with poor glycemic control—a population typically at higher risk of complications.
🧠 Why Might This Be?
GLP-1RAs have been shown to have anti-inflammatory effects in both preclinical and clinical settings. This pleiotropic action has prompted research not only in cardiovascular disease but also in COVID-19 outcomes, nonalcoholic steatohepatitis, and autoimmune diseases such as psoriasis and rheumatoid arthritis. The authors propose that this anti-inflammatory capacity may help mitigate infection-related complications in diabetes—especially in the lungs and the feet, two common sites of morbidity.
Interestingly, DPP-4 inhibitors—despite targeting the same incretin axis—do not share the same anti-inflammatory profile, which may help explain the observed differences in hospitalization outcomes.
🦶 Implications for Diabetic Foot Care
For clinicians focused on limb preservation and wound prevention, this study introduces an additional consideration when selecting glucose-lowering agents. The observed lower rate of hospitalization for diabetic foot infections in GLP-1RA users suggests these medications may offer benefit beyond glycemic control—possibly helping to reduce recidivism and delay progression from infection to amputation.
📌 Final Thoughts
While these results don’t prove causality, they do underscore the growing case for GLP-1RAs as potentially beneficial across a wide range of diabetes-related complications. Given the persistent burden of infection-related hospitalization in diabetes, especially in the foot and lower respiratory tract, further investigation is warranted. For now, this study offers compelling real-world evidence that may help tip the balance when choosing among second-line therapies.
Citation:
Wang JL, Lee CC, Ko WC, Wu LC, Chang CH. GLP-1 receptor agonists and hospitalization due to infections in patients with type 2 diabetes: A nationwide cohort study. Diabetes Res Clin Pract. 2025;112324. https://doi.org/10.1016/j.diabres.2025.112324
Leave a Reply